Among the key players, Sun Pharma is making strategic moves to enter this high-growth segmentespecially targeting the U.S
Results vary, but patients typically begin to see the effects of their treatment after one month of their program, with many first experiencing increased feelings of satiety
Starting with the 2026 QP performance period, the Threshold Score for an APM Entity or eligible clinician is calculated as a percent by dividing the value described under paragraph (e)(1) of this section by the value described under paragraph (e)(2) of this section
These injections are commonly used to manage type 2 diabetes and have been approved for weight loss in certain individuals
Improper Storage and Handling Leaving reconstituted peptides at room temperature or exposing them to violent shaking degrades their molecular structure quickly
The response from many of those employers has been swift: Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the start of 2026 Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026 HCA Healthcare one of the countrys largest hospital systems notified employees that its GLP-1 coverage was ending after usage surged 90% in a single year, directing workers instead toward manufacturer cash-pay programs Several other employers have stopped short of elimination but have tightened requirements dramatically restricting coverage only to patients with a formal diabetes diagnosis and removing access for patients using GLP-1s for weight management alone. Why Are Employers Cutting This Coverage Now